Acute Sinusitis: Distinguishing and Treating Bacterial Disease
Clinical Practice Update — Separating Viral From Bacterial Rhinosinusitis and Using Antibiotics Wisely
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Distinguishing viral from acute bacterial sinusitis and rational antibiotic use in adults
- Target Audience
- Family physicians, primary care clinicians, nurse practitioners, pharmacists, residents
- Setting
- Primary care, urgent care, outpatient
- Source Evidence
- •IDSA Clinical Practice Guideline on Acute Bacterial Rhinosinusitis (2012)
- •AAO-HNS Clinical Practice Guideline: Adult Sinusitis Update (2015)
- •Cochrane Review — Antibiotics for Acute Rhinosinusitis in Adults (2018)
- •NICE Guideline NG79 — Sinusitis (Acute): Antimicrobial Prescribing (2017)
Key Clinical Takeaways
Most patients you see with sinus symptoms have a self-limiting viral illness, yet acute bacterial sinusitis is one of the most common reasons antibiotics are prescribed unnecessarily. The fastest way to get the decision right is to anchor on symptom timing: the overwhelming majority of cases that follow an ordinary upper respiratory tract infection resolve without antibiotics. The points below distil the evidence into actionable rules for the bedside.
- 1Suspect a bacterial cause only when symptoms persist beyond 10 days, are severe from onset, or worsen after initial improvement.
- 2Coloured nasal discharge alone does not indicate bacterial infection and is not a reason to prescribe.
- 3Offer watchful waiting with a safety net for uncomplicated acute bacterial sinusitis rather than immediate antibiotics.
- 4When antibiotics are warranted, amoxicillin or amoxicillin-clavulanate is the first choice for most adults.
- 5Reserve respiratory fluoroquinolones for genuine beta-lactam allergy with no safer alternative.
- 6Intranasal corticosteroids and saline irrigation give the most reliable symptom relief; oral decongestants offer little.
- 7Escalate urgently for orbital, intracranial, or systemic red flags rather than continuing oral therapy.
- 8Reassess at 7 days if symptoms have not improved or have worsened on the chosen strategy.
Distinguishing Viral Rhinosinusitis From Acute Bacterial Sinusitis
The clinical challenge in acute bacterial sinusitis is that its early presentation is indistinguishable from a common cold. Both produce nasal obstruction, facial pressure, and discharge. What separates the two is the pattern over time, not any single symptom on a given day.
Evaluate symptom duration as the primary discriminator. Suspect bacterial involvement when typical symptoms persist without improvement for at least 10 days, which exceeds the natural course of most viral illness.
Strong Rec Moderate Evidence IDSA 2012 AAO-HNS 2015Recognise the worsening-after-improvement pattern, sometimes called double sickening, as a strong pointer to a bacterial cause. A patient who improves around day 5 then deteriorates with renewed fever or facial pain fits this picture.
Strong Rec Moderate Evidence IDSA 2012Identify severe-onset disease when high fever and purulent discharge or marked facial pain appear together at the start and last several consecutive days. This presentation justifies earlier consideration of treatment.
Moderate Rec Low Evidence IDSA 2012Do not use discharge colour or thickness as a marker of bacterial infection. Purulent-appearing secretions reflect neutrophil activity that occurs in viral illness too and should not drive prescribing.
Against Moderate Evidence AAO-HNS 2015When to Prescribe Antibiotics in Acute Bacterial Sinusitis
Even when criteria for acute bacterial sinusitis are met, antibiotics are not automatic. Pooled trial data show that a large proportion of patients recover on their own within two weeks, and the absolute benefit of treatment is modest while the harms — rash, gastrointestinal upset, and resistance — are real.
Offer watchful waiting for up to 7 days as a first-line option in uncomplicated acute bacterial sinusitis, supported by clear safety-net advice and easy access to follow-up. This is a cornerstone of antibiotic stewardship in this condition.
Strong Rec High Evidence AAO-HNS 2015 NICE NG79 2017Initiate antibiotics promptly when the patient is severely unwell, deteriorating, immunocompromised, or has failed an adequate period of watchful waiting. Lower the threshold to treat in frail or high-risk patients.
Strong Rec Moderate Evidence IDSA 2012Consider a delayed prescription that the patient fills only if symptoms fail to improve within an agreed window. This reduces total antibiotic use while preserving a safety valve.
Moderate Rec Moderate Evidence NICE NG79 2017Choosing the Right Antibiotic
When a decision to treat is made, the goal is to cover the usual respiratory pathogens — pneumococcus, Haemophilus influenzae, and Moraxella catarrhalis — with the narrowest effective agent. Guidance differs on whether to favour plain amoxicillin or to add clavulanate up front, and local resistance shapes that choice.
Prescribe amoxicillin-clavulanate (typically 500/125 mg three times daily, or 875/125 mg twice daily) as first-line when treatment is indicated, reflecting rising beta-lactamase–producing organisms. Plain amoxicillin remains a reasonable first choice where resistance is low.
Strong Rec Moderate Evidence IDSA 2012For confirmed penicillin allergy, prescribe doxycycline as the preferred alternative; it retains good respiratory coverage and is well tolerated in adults. Use a macrolide only where local pneumococcal macrolide resistance is known to be low.
Moderate Rec Moderate Evidence IDSA 2012Do not use respiratory fluoroquinolones as routine first-line therapy. Reserve them for patients who cannot take any beta-lactam and have no suitable alternative, given their serious safety profile.
Against Moderate Evidence FDA Safety CommunicationTreat for a short course — commonly 5 to 7 days in adults — rather than a prolonged one, as shorter courses are as effective for uncomplicated disease and reduce adverse effects.
Strong Rec Moderate Evidence NICE NG79 2017Antibiotic Options: A Drug-by-Drug Guide
| Drug | Typical Adult Dose | Best Suited For | Practical Tips |
|---|---|---|---|
| Amoxicillin-clavulanate | 500/125 mg TID or 875/125 mg BID | First-line where resistance is a concern | Take with food to reduce GI upset. Counsel on diarrhoea. |
| Amoxicillin | 500 mg TID | First-line where local resistance is low | Safe in pregnancy. Simplest, narrowest option. |
| Doxycycline | 100 mg BID | Penicillin allergy, preferred alternative | Take upright with water. Avoid in pregnancy. |
| Doxycycline (load) | 200 mg day 1, then 100 mg daily | Alternative dosing for the above | Photosensitivity — advise sun protection. |
| Levofloxacin | 500 mg daily | Last resort only | FDA black box warnings. Avoid if any alternative exists. |
Symptomatic and Adjunctive Care
Whether or not antibiotics are used, symptom relief is what most patients actually want. The interventions with the best supporting evidence are simple and inexpensive, and they apply equally to viral disease and to acute bacterial sinusitis.
Advise intranasal corticosteroids as adjunctive therapy to ease congestion and facial pressure, particularly in patients with a background of allergic rhinitis.
Moderate Rec Moderate Evidence AAO-HNS 2015Recommend saline nasal irrigation to improve comfort and clearance. It is cheap, safe, and a useful first thing to suggest at the initial visit.
Moderate Rec Low Evidence AAO-HNS 2015Counsel patients on analgesia — paracetamol or an NSAID — for pain and fever, which addresses the symptoms that trouble patients most.
Strong Rec Low Evidence NICE NG79 2017Avoid routine use of oral decongestants and antihistamines for symptom control in non-allergic patients, as the benefit is small and side effects are common.
Conditional Rec Low Evidence AAO-HNS 2015Recognising Complications and Red Flags
Serious complications are rare, but they are time-critical when they occur. The eye and the central nervous system are the territories that matter, because infection can spread from the sinuses to adjacent structures.
Refer urgently for periorbital swelling, eye redness, proptosis, painful or restricted eye movements, or visual change, which may signal orbital cellulitis.
Strong Rec Moderate Evidence NICE NG79 2017Refer urgently for severe headache, neck stiffness, focal neurology, or altered consciousness, which raise concern for intracranial spread.
Strong Rec Moderate Evidence NICE NG79 2017Evaluate for symptoms recurring four or more times a year, or persisting beyond 12 weeks, as a prompt to reconsider the diagnosis and refer for specialist assessment of chronic disease.
Moderate Rec Low Evidence AAO-HNS 2015Clinical Decision Pathway
A practical, question-based approach to the patient in front of you. Work through the questions in order.
Monitoring and Follow-Up
| Checkpoint | When | What to Look For | Common Pitfalls |
|---|---|---|---|
| Symptom trajectory | Day 7 of the chosen strategy | Clear improvement in pain, fever, and congestion | Switching antibiotics at 48h for residual discharge alone |
| Treatment failure | No better or worse by day 7 | Reconsider diagnosis; broaden cover if first-line failed | Repeating the same agent without reassessing |
| Red flags | At every contact | Orbital, intracranial, or systemic warning signs | Attributing eye or neuro signs to ordinary sinus pain |
| Recurrence | Over months | Four or more episodes a year prompts referral | Treating recurrent disease as isolated acute events |
Evidence in Context
What the evidence shows, where the major guidelines align, and where their emphasis differs.
Where the Guidelines Agree
There is broad consensus that diagnosis rests on the clinical pattern over time, that most patients do not need antibiotics, that a beta-lactam is the agent of choice when treatment is indicated, and that fluoroquinolones should be held in reserve.
First-Line Agent: Amoxicillin or Amoxicillin-Clavulanate
North American guidance has favoured adding clavulanate up front to counter beta-lactamase–producing organisms, whereas some other frameworks retain plain amoxicillin as first-line where resistance is low. The right default depends on local susceptibility data.
The Modest Benefit of Antibiotics
Systematic review evidence indicates that antibiotics shorten illness only marginally and that many patients must be treated for one additional person to benefit, while a meaningful fraction experience adverse effects. This underpins the case for watchful waiting.
The Role of Adjunctive Therapy
Intranasal corticosteroids have the most consistent supportive data among adjuncts, particularly with allergic background, while evidence for oral decongestants and antihistamines is weak. Saline irrigation is low-risk and reasonable to recommend.
References
- 1.Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72–e112. doi:10.1093/cid/cir1043
- 2.Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2 Suppl):S1–S39. doi:10.1177/0194599815572097
- 3.Lemiengre MB, van Driel ML, Merenstein D, et al. Antibiotics for acute rhinosinusitis in adults. Cochrane Database Syst Rev. 2018;9:CD006089. doi:10.1002/14651858.CD006089.pub5
- 4.NICE Guideline [NG79]. Sinusitis (acute): antimicrobial prescribing. 2017. nice.org.uk/guidance/ng79
- 5.Harris AM, Hicks LA, Qaseem A. Appropriate antibiotic use for acute respiratory tract infection in adults. Ann Intern Med. 2016;164(6):425–434. doi:10.7326/M15-1840
How to Read the Evidence Tags
Every recommendation carries tags for recommendation strength and evidence quality — Medaptly’s own simplified interpretations, not any guideline body’s classification system.
Recommendation Strength
| Tag | What It Means |
|---|---|
| Strong Rec | High-quality evidence broadly supports this action. |
| Moderate Rec | The weight of evidence favours this action. |
| Conditional Rec | The benefit is less certain — individualise. |
| Against | Evidence shows no benefit or potential harm. |
Evidence Quality
| Tag | What It Means |
|---|---|
| High Evidence | Multiple well-designed RCTs or high-quality meta-analyses. |
| Moderate Evidence | Single RCT or large observational studies. |
| Low Evidence | Expert consensus or small studies. |